Skip to main content

Table 1 Characteristics of the identification cohort (nasal epithelial brushes) and comparator cohorts (bronchial epithelial brushes)

From: Nasal gene expression differentiates COPD from controls and overlaps bronchial gene expression

 

Identification cohort

Comparator cohorts

 

Nasal brushes

Bronchial brushes (cohort 1)

Bronchial brushes (cohort 2)

 

COPD

( n = 31)

Control

(n = 22)

p

COPD

( n = 87)

Control

( n = 151)

p

COPD

( n = 10)

Control

(n = 20)

p

Age, years

61

(8)

52

(8)

<0.01

65

(6)

64

(6)

0.25

67

(5)

55

(10)

<0.01

Male gender, n (%)

21

(68%)

14

(64%)

0.76

52

(60%)

83

(55%)

0.50

10

(100%)

17

(85%)

0.20

Smoking status

 Current smoking, n (%)

31

(100%)

22

(100%)

1

30

(35%)

69

(46%)

0.10

8

(80%)

19

(95%)

0.20

 Ex smoking, n (%)

0

(0%)

0

(0%)

57

(66%)

82

(54%)

2

(20%)

1

(5%)

Packyears

39

(18)

29

(12)

0.03

51 a

(25)

47 a

(19)

0.11

31 b

(22-45)

26 b

(24-36)

0.57

ICS use, n (%)

27

(87%)

–

 

<0.01

18

(21%)

7

(5%)

<0.01

8

(80%)

0

(0%)

<0.01

FEV 1 c , % predicted

31

(6)

102

(11)

<0.01

60

(14)

93

(13)

<0.01

62 b

(52-68)

102 b

(97-114)

<0.01

FEV 1 /FVC, %

34

(8)

75

(4)

<0.01

56

(9)

75

(6)

<0.01

50 b

(42-56)

73 b

(71-83)

<0.01

GOLD classification c

 GOLD 1, n (%)

0

(0%)

–

 

–

0

(0%)

–

 

–

1

(10%)

–

 

–

 GOLD 2, n (%)

2

(6%)

–

 

–

68

(78%)

–

 

–

8

(80%)

–

 

–

 GOLD 3, n (%)

22

(71%)

–

 

–

17

(20%)

–

 

–

1

(10%)

–

 

–

 GOLD 4, n (%)

7

(23%)

–

 

–

2

(2%)

–

 

–

0

(0%)

–

 

–

TLC, % predicted

132

(17)

105

(10)

<0.01

n/a

 

n/a

 

–

n/a

 

n/a

 

–

RV/TLC, %

62

(7)

30

(3)

<0.01

n/a

 

n/a

 

–

n/a

 

n/a

 

–

CCQ

2.4

(0.9)

0.4

(0.3)

<0.01

n/a

 

n/a

 

–

n/a

 

n/a

 

–

Allergic rhinitis, n (%)

1

(3%)

5

(23%)

0.07

n/a

 

n/a

 

–

n/a

 

n/a

 

–

Nasal CS use, n (%)

2

(7%)

1

(5%)

0.99

n/a

 

n/a

 

–

n/a

 

n/a

 

–

  1. All values are presented as mean with standard deviation, unless stated otherwise; p -values reflect differences between COPD and controls
  2. a Missing packyears for 5 subjects with COPD and 11 controls
  3. b Median with interquartile range
  4. c postbronchodilator, except for 1 subject in the identification cohort for which postbronchodilator FEV 1 was not available, we show prebronchodilator FEV 1 instead (32%); for all subjects in cohort 1, only prebronchodilator FEV 1 was available
  5. ICS Inhaled corticosteroids, FEV 1 Forced expiratory volume in 1 s, FVC Forced vital capacity, GOLD Global initiative for chronic obstructive lung disease, TLC Total lung capacity, RV Residual volume, CCQ Clinical COPD Questionnaire, CS Corticosteroids, n/a Not available
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us